METTL14 has also been implicated as an oncogene in breast cancer, another endocrine-driven cancer (Yi et al., 2020), as well as in pancreatic cancer and AML (Weng et al., 2018; Paris et al., 2019; Kong et al., 2020; Wang et al., 2020b). This evidence concerns the gene METTL14 and pancreatic neoplasm.